文献速递角膜与眼表疾病

第二代ELZA-sub400方案:超薄圆锥角膜个体化高能量交联

Second-Generation ELZA-sub400 Protocol: Individualized High-Fluence Cross-Linking for Ultra-Thin Keratoconus Corneas.
PubMed 文献 · Am J Ophthalmol · 2026-06-27

回顾性单中心连续病例系列纳入29眼超薄(浸泡后最薄基质厚度<400µm)进展性圆锥角膜或LASIK后扩张,采用第二代个体化高能量UV-A交联(ELZA-sub400)。12个月时76%眼无进展(Kmax增加<1.0D),角膜分界线均位于基质内,无内皮失代偿,但镜片矫正视力数值下降未达统计学显著。

要点

  • 超薄角膜(<400µm)行高能量个体化交联,12个月无进展率76%。
  • 分界线均局限于基质层,无深基质混浊或内皮失代偿。
  • 镜片矫正视力数值下降未达统计学显著,但临床需关注。

核心结论

  • 第二代ELZA-sub400交联在12个月时使76%的超薄角膜扩张停止进展,短期安全性可接受。

研究设计与样本

  • 回顾性、单中心、连续干预性病例系列,纳入24例患者29眼,术后12个月评估。

主要发现

  • 22/29眼(76%;95%CI 57.9%-87.8%)在12个月满足无进展标准(Kmax增加<1.0D)。
  • 分界线至前基质距离205±64µm(95%CI 180.7-229.3),至内皮距离64µm(IQR 49-152)。
  • 15/29眼(51.7%)分界线距内皮≤70µm,所有分界线均位于基质层内。

关键数值与推荐

  • 无进展定义为12个月Kmax增加<1.0D。
  • 紫外线波长365nm,辐照度3或9mW/cm²,总能量根据术中超声测厚和列线图滴定至最高10J/cm²,目标未交联基质边缘距内皮约70µm。

临床怎么用

  • 对浸泡后最薄基质厚度<400µm的进展性圆锥角膜或LASIK后扩张,可考虑个体化高能量交联方案。
  • 术中需用超声测厚和列线图滴定能量,确保分界线局限于基质层并保留安全内皮距离。
  • 术后需监测镜片矫正视力变化,尽管数值下降未达统计学显著,但临床意义需关注。

局限性

  • 回顾性、单中心、小样本(29眼),随访仅12个月。
  • 镜片矫正视力数值下降虽未达统计学显著,但需更大前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of a second-generation individualized corneal cross-linking (CXL) protocol (ELZA-sub400) using high-fluence UV-A irradiation in ultrathin ectatic corneas. DESIGN: Retrospective, single-center, consecutive interventional case series. METHODS: Twenty-nine eyes of 24 patients with progressive keratoconus or post-LASIK ectasia and a post-soak intraoperative thinnest stromal thickness <400 µm were included. After epithelial removal and riboflavin soaking, continuous UV-A irradiation (365 nm) at 3 or 9 mW/cm² was delivered with total fluence titrated up to 10 J/cm² based on intraoperative ultrasound pachymetry and a previously published nomogram targeting an uncross-linked stromal margin of approximately 70 µm above the endothelium. Outcomes were assessed at baseline and up to 12 months using corrected distance visual acuity (CDVA) and corneal parameters measured using Scheimpflug tomography and anterior segment OCT (AS-OCT) with Placido-based topography. The main outcome measure was the proportion of eyes without progression at 12 months, defined as <1.0 D increase in maximum keratometry (Kmax). Secondary outcomes included changes in CDVA, refraction, Kmax, stromal thickness, demarcation line depth, densitometry, and safety parameters. RESULTS: At 12 months, 22/29 eyes (76%; 95% CI, 57.9%-87.8%) met the nonprogression criterion. Mean change in Kmax was -0.77 ± 5.10 D (95% CI, -2.71 to 1.17; P = .418). Mean demarcation line-to-anterior stroma distance was 205 ± 64 µm (95% CI, 180.7-229.3), and demarcation line-to-endothelium distance was 64 µm (IQR, 49-152). All demarcation lines remained within the stromal layer; 15/29 eyes (51.7%) had a demarcation line located ≤70 µm from the endothelium. Median CDVA changed from 0.10 to 0.32 logMAR (P = .142). Minimum stromal thickness showed a median change of -4.0 µm (P = .309). No significant change was observed in densitometry, and no eye developed deep stromal haze or endothelial decompensation. CONCLUSIONS: Second-generation ELZA-sub400 CXL halted ectasia progression in 76% of ultrathin corneas at 12 months and was associated with an acceptable short-term safety profile, including stromal-confined demarcation line formation and no observed endothelial decompensation. The numerical decline in spectacle CDVA observed in this severely affected cohort did not reach statistical significance but is clinically important and warrants confirmation in larger prospective studies.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hafezi F, Akcan RE, Kling S, et al. Second-Generation ELZA-sub400 Protocol: Individualized High-Fluence Cross-Linking for Ultra-Thin Keratoconus Corneas. Am J Ophthalmol. 2026. PMID: 42364705. doi:10.1016/j.ajo.2026.06.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。